Covidien says FDA extends review on pain drug Exalgo to Feb. 22
Covidien says FDA extends Exalgo review NEW YORK — Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo. Antigenics withdraws Oncophage application in Europe following negative recommendation |